30th October, 2026

To,
All Directors
Kilich Drugs (India) Limited

Dear Sir,

Notice is hereby given that a Meeting bearing no. BM – 5/2026-27 of the Board of Directors of Kilitch Drugs (India) Limited will be held on Friday, 6th November, 2026 at Corporate Office of the Company at 37, Ujagar Industrial Estate, W. T. Patil Marg, Deonar, Mumbai - 400088 MH IN at 4:30 pm

The detailed agenda is enclosed along with this notice.

Kindly make it convenient to attend the same.

Thanking you,

Yours Faithfully,

For **KILITCH DRUGS (INDIA) LIMITED**

SD/-

PUSHPA NYOUPANE
COMPANY SECRETARY

Agenda for the Meeting bearing no. BM – 5/2026-27 of the Board of Directors of Kilitch Drugs (India) Limited for the Financial Year 2026-27 to be held at Corporate Office of the Company at 37, Ujagar Industrial Estate, W. T. Patil Marg, Deonar, Mumbai - 400088 MH IN on Friday, 6th November, 2026 at 4:30 pm

Sr. No.	Particulars
1	To Elect the Chairman of the Meeting
2	To grant leave of absence to Directors
3	To consider and adopt unaudited Standalone and Consolidated Financial Results for the quarter ended and half year ended 30th September, 2026 under Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
4	Any other business item with the permission of the Chairman

Item No. 1 To elect the Chairman of the meeting

Item No. 2 To grant leave of absence to Directors

Item No. 3 To consider and adopt unaudited Standalone and Consolidated Financial Results for the quarter ended 30th September, 2026 and year to date under Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Board is hereby informed that pursuant to Regulation 33(2) and 33(3)(a) of SEBI (LODR) Regulations, 2015 quarterly and year to date financial results shall be approved by the Board of Directors and submit the same along with limited review report to stock exchanges within 45 days from the end of the quarter. The financial results for the quarter ended 30th September, 2026 and year to date will be placed before the Board at the meeting.

The Board is hereby requested to approve the same by passing following resolution;

"**RESOLVED THAT** the un-audited Financial Results for the quarter ended 30th September, 2026 and year to date in accordance with Regulation 33(3)(a) of SEBI (Listing Obligation & Disclosure Requirements) Regulation 2015, be and is hereby approved and Mr. Mukund Mehta, Managing Director, Mr. Bhavin Mehta Whole-time Director and Mrs. Mira Mehta, Managing Director of the Company be and are hereby authorized, severally, to sign the Results and send the same to the Stock Exchanges.

RESOLVED FURTHER THAT the un-audited Financial Results for the quarter ended 30th September, 2026 and year to date, duly signed by the above mentioned authorised signatories, be forwarded to the Auditors for their Limited Review Report thereon in accordance with Regulation 33(3)(a) of SEBI (Listing Obligation & Disclosure Requirements) Regulation 2015 and to stock exchanges along with Limited review report.

RESOLVED FURTHER THAT, the un-audited results as placed on the table be published in the newspapers as per the latest format prescribed by the Securities and Exchange Board of India (Listing Obligations and Disclosure requirements) Regulations, 2015."

Item No. 4 Any other item with the permission of the Chairman